{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreielm2zijozagxb7f7jmk2zzsv2pmfvjdpaaatb5cntnc3zxxgarnu",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mejioxx6xkt2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreid5k4i7abgny54wzm3lw3mym2vexadcijihfdw4ipa35hea3kmyde"
    },
    "mimeType": "image/jpeg",
    "size": 460063
  },
  "path": "/news/2026-02-global-major-treatment-advance-tough.html",
  "publishedAt": "2026-02-10T12:29:19.000Z",
  "site": "https://medicalxpress.com",
  "tags": [
    "Oncology & Cancer"
  ],
  "textContent": "Results from a new clinical trial led by Wake Forest University School of Medicine and Atrium Health Levine Cancer show that a new therapy could provide significantly better outcomes for patients with high-risk essential thrombocythaemia (ET), a type of blood cancer. The findings were recently published in The Lancet Haematology.",
  "title": "Global study marks major treatment advance for tough-to-treat high-risk blood cancer"
}